126 related articles for article (PubMed ID: 38385970)
41. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
42. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
Tiwari S; Goel V; John MC; Patnaik N; Doval DC
Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
[TBL] [Abstract][Full Text] [Related]
44. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Taguchi J; Shimizu Y; Ariga S; Goda T; Ohhara Y; Honma R; Noguchi T; Takeuchi S; Kinoshita I; Amano T; Mizumachi T; Kano S; Takahara M; Abe T; Homma A; Dosaka-Akita H
Int J Clin Oncol; 2021 Jan; 26(1):51-58. PubMed ID: 32996023
[TBL] [Abstract][Full Text] [Related]
45. Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.
Adkins D; Ley J; Atiq O; Powell S; Spanos WC; Gitau M; Rigden C; Palka K; Liu J; Oppelt P
Oral Oncol; 2021 Apr; 115():105173. PubMed ID: 33548860
[TBL] [Abstract][Full Text] [Related]
46. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).
Fury MG; Sherman EJ; Rao SS; Wolden S; Smith-Marrone S; Mueller B; Ng KK; Dutta PR; Gelblum DY; Lee JL; Shen R; Kurz S; Katabi N; Haque S; Lee NY; Pfister DG
Ann Oncol; 2014 Mar; 25(3):689-694. PubMed ID: 24496920
[TBL] [Abstract][Full Text] [Related]
47. Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients.
Meirovitz A; Bergerson S; Hirshoren N; Weinberger JM; Bersudski E; Daniel S; Sheva K; Perez CA
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1479. PubMed ID: 34184405
[TBL] [Abstract][Full Text] [Related]
48. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
49. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
50. Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Fushimi C; Baba D; Masubuchi T; Yamazaki M; Kitani Y; Kitajima T; Tanaka J; Hanyu K; Tanaka N; Miura K; Tada Y
In Vivo; 2020; 34(5):2653-2657. PubMed ID: 32871796
[TBL] [Abstract][Full Text] [Related]
51. Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
Ham JC; van Meerten E; Fiets WE; Beerepoot LV; Jeurissen FJF; Slingerland M; Jonker MA; Husson O; van der Graaf WTA; van Herpen CML
Head Neck; 2020 May; 42(5):828-838. PubMed ID: 31903657
[TBL] [Abstract][Full Text] [Related]
52. An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Cavalieri S; Serafini MS; Carenzo A; Canevari S; Lenoci D; Pistore F; Miceli R; Vecchio S; Ferrari D; Moro C; Sponghini A; Caldara A; Rocca MC; Secondino S; Moretti G; Denaro N; Caponigro F; Vaccher E; Rinaldi G; Ferraù F; Bossi P; Licitra L; De Cecco L
Cells; 2022 Oct; 11(19):. PubMed ID: 36231138
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors.
Lai CL; Chen TH; Chang PM; Tai SK; Chu PY; Yang MH
J Chin Med Assoc; 2022 Jun; 85(6):687-692. PubMed ID: 35507025
[TBL] [Abstract][Full Text] [Related]
54. Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma.
Ramakrishnan K; Liu Z; Baxi S; Chandwani S; Joo S; Chirovsky D
Future Oncol; 2021 Aug; 17(23):3037-3050. PubMed ID: 34044594
[TBL] [Abstract][Full Text] [Related]
55. Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck.
Nishimura A; Yokota T; Hamauchi S; Onozawa Y; Shirasu H; Kawabata T; Ogawa H; Onoe T; Iida Y; Mukaigawa T; Yasui H
Int J Clin Oncol; 2021 Oct; 26(10):1822-1830. PubMed ID: 34152533
[TBL] [Abstract][Full Text] [Related]
56. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
Seiwert TY; Kochanny S; Wood K; Worden FP; Adkins D; Wade JL; Sleckman BG; Anderson D; Brisson RJ; Karrison T; Stadler WM; Vokes EE
Cancer; 2020 Jul; 126(14):3237-3243. PubMed ID: 32365226
[TBL] [Abstract][Full Text] [Related]
57. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
58. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
59. How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
Szturz P; Seiwert TY; Vermorken JB
J Clin Oncol; 2017 Jul; 35(20):2229-2231. PubMed ID: 28471725
[No Abstract] [Full Text] [Related]
60. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J; Kono SA; Lewis C; Chen AY; Higgins K; El-Deiry M; Wadsworth T; Beitler JJ; Shin DM; Sun SY; Khuri FR
Cancer; 2014 Dec; 120(24):3940-51. PubMed ID: 25103371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]